mapkap1 msin1  (Danaher Inc)


Bioz Verified Symbol Danaher Inc is a verified supplier
Bioz Manufacturer Symbol Danaher Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Danaher Inc mapkap1 msin1
    Mapkap1 Msin1, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapkap1 msin1/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mapkap1 msin1 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    mapkap1 msin1  (Abcam)

     
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Abcam mapkap1 msin1
    Inhibiting p110 activates CMA in NIH3T3 cells. (A) Western blots showing effects of selected doses of buparlisib (2 µM), pictilisib (500 nM), and copanlisib (50 nM) on phosphorylation of Akt, <t>MAPKAP1,</t> and GFAP. Blots are representative of six experimental replicates. DMSO is the solvent control for buparlisib and pictilisib. TFA is the solvent control for copanlisib. (B) Quantification of GFAP phosphorylation change in response to p110 inhibitors, as shown in A, n = 6. For C–H, data points are pooled from at least three independent experiments. (C and D) 10 h buparlisib treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 92 cells; buparlisib = 83 cells. (E and F) 10 h pictilisib treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 71 cells; pictilisib = 86 cells. (G and H) 10 h copanlisib treatment induces the accumulation of Dendra2 CMA reporter puncta. TFA = 132 cells; copanlisib = 116 cells. (I–K) Effects of buparlisib, pictilisib, and copanlisib on macroautophagy, as measured by LC3-II flux, n = 6. For all experiments, cells were maintained in complete growth medium with 10% serum. P values written above brackets are derived from unpaired t tests. **, P < 0.01 by unpaired t test. For charts in I – K, P INT is the interaction term P value from a two-way ANOVA. Error bars are SEM. Scale bars are 20 µm. ACTB, β-Actin; Bup, buparlisib; Cop, copanlisib; Pic, pictilisib; TFA, trifluoroacetic acid.
    Mapkap1 Msin1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapkap1 msin1/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mapkap1 msin1 - by Bioz Stars, 2024-09
    86/100 stars

    Images

    1) Product Images from "Inhibition of class I PI3K enhances chaperone-mediated autophagy"

    Article Title: Inhibition of class I PI3K enhances chaperone-mediated autophagy

    Journal: The Journal of Cell Biology

    doi: 10.1083/jcb.202001031

    Inhibiting p110 activates CMA in NIH3T3 cells. (A) Western blots showing effects of selected doses of buparlisib (2 µM), pictilisib (500 nM), and copanlisib (50 nM) on phosphorylation of Akt, MAPKAP1, and GFAP. Blots are representative of six experimental replicates. DMSO is the solvent control for buparlisib and pictilisib. TFA is the solvent control for copanlisib. (B) Quantification of GFAP phosphorylation change in response to p110 inhibitors, as shown in A, n = 6. For C–H, data points are pooled from at least three independent experiments. (C and D) 10 h buparlisib treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 92 cells; buparlisib = 83 cells. (E and F) 10 h pictilisib treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 71 cells; pictilisib = 86 cells. (G and H) 10 h copanlisib treatment induces the accumulation of Dendra2 CMA reporter puncta. TFA = 132 cells; copanlisib = 116 cells. (I–K) Effects of buparlisib, pictilisib, and copanlisib on macroautophagy, as measured by LC3-II flux, n = 6. For all experiments, cells were maintained in complete growth medium with 10% serum. P values written above brackets are derived from unpaired t tests. **, P < 0.01 by unpaired t test. For charts in I – K, P INT is the interaction term P value from a two-way ANOVA. Error bars are SEM. Scale bars are 20 µm. ACTB, β-Actin; Bup, buparlisib; Cop, copanlisib; Pic, pictilisib; TFA, trifluoroacetic acid.
    Figure Legend Snippet: Inhibiting p110 activates CMA in NIH3T3 cells. (A) Western blots showing effects of selected doses of buparlisib (2 µM), pictilisib (500 nM), and copanlisib (50 nM) on phosphorylation of Akt, MAPKAP1, and GFAP. Blots are representative of six experimental replicates. DMSO is the solvent control for buparlisib and pictilisib. TFA is the solvent control for copanlisib. (B) Quantification of GFAP phosphorylation change in response to p110 inhibitors, as shown in A, n = 6. For C–H, data points are pooled from at least three independent experiments. (C and D) 10 h buparlisib treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 92 cells; buparlisib = 83 cells. (E and F) 10 h pictilisib treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 71 cells; pictilisib = 86 cells. (G and H) 10 h copanlisib treatment induces the accumulation of Dendra2 CMA reporter puncta. TFA = 132 cells; copanlisib = 116 cells. (I–K) Effects of buparlisib, pictilisib, and copanlisib on macroautophagy, as measured by LC3-II flux, n = 6. For all experiments, cells were maintained in complete growth medium with 10% serum. P values written above brackets are derived from unpaired t tests. **, P < 0.01 by unpaired t test. For charts in I – K, P INT is the interaction term P value from a two-way ANOVA. Error bars are SEM. Scale bars are 20 µm. ACTB, β-Actin; Bup, buparlisib; Cop, copanlisib; Pic, pictilisib; TFA, trifluoroacetic acid.

    Techniques Used: Western Blot, Derivative Assay

    Inhibiting PDPK1 activates CMA in NIH3T3 cells. (A) Western blots showing effects of selected doses of BX795 (5 µM), BX912 (15 µM), and GSK2334470 (5 µM) on phosphorylation of Akt, MAPKAP1, and GFAP. Blots are representative of six experimental replicates. DMSO is the solvent control for all of the drugs. (B) Quantification of GFAP phosphorylation change in response to PDPK1 inhibitors, as shown in A, n = 6. In A and B, GSK2334470 is abbreviated for space, as GSK233. For C – H, data points are pooled from at least three independent experiments. (C and D) 10 h BX795 treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 88 cells; BX795 = 90 cells. (E and F) 10 h BX912 treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 155 cells; BX912 = 120 cells. (G and H) 10 h GSK2334470 treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 145 cells; GSK2334470 = 144 cells. (I–K) Effects of BX795, BX912, and GSK233470 on macroautophagy, as measured by LC3-II flux, n = 6. For all experiments, cells were maintained in complete growth medium with 10% serum. P values written above brackets are derived from unpaired t tests. **, P < 0.01 by unpaired t test. For charts in I–K, P INT is the interaction term P value from a two-way ANOVA. Error bars are SEM. Scale bars are 20 µm. ACTB, β-Actin.
    Figure Legend Snippet: Inhibiting PDPK1 activates CMA in NIH3T3 cells. (A) Western blots showing effects of selected doses of BX795 (5 µM), BX912 (15 µM), and GSK2334470 (5 µM) on phosphorylation of Akt, MAPKAP1, and GFAP. Blots are representative of six experimental replicates. DMSO is the solvent control for all of the drugs. (B) Quantification of GFAP phosphorylation change in response to PDPK1 inhibitors, as shown in A, n = 6. In A and B, GSK2334470 is abbreviated for space, as GSK233. For C – H, data points are pooled from at least three independent experiments. (C and D) 10 h BX795 treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 88 cells; BX795 = 90 cells. (E and F) 10 h BX912 treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 155 cells; BX912 = 120 cells. (G and H) 10 h GSK2334470 treatment induces the accumulation of Dendra2 CMA reporter puncta. DMSO = 145 cells; GSK2334470 = 144 cells. (I–K) Effects of BX795, BX912, and GSK233470 on macroautophagy, as measured by LC3-II flux, n = 6. For all experiments, cells were maintained in complete growth medium with 10% serum. P values written above brackets are derived from unpaired t tests. **, P < 0.01 by unpaired t test. For charts in I–K, P INT is the interaction term P value from a two-way ANOVA. Error bars are SEM. Scale bars are 20 µm. ACTB, β-Actin.

    Techniques Used: Western Blot, Derivative Assay

    Effects of PI3K inhibitors on CMA and macroautophagy in AML12 cells. (A–C) Dose curves in AML12 cells for buparlisib, pictilisib, and autophinib, respectively. (D) Western blots demonstrating the effects of buparlisib (5 µM), pictilisib (2 µM), and autophinib (5 µM) on phosphorylation of Akt, MAPKAP1, and GFAP. Blots are representative of six experimental replicates. DMSO is the solvent control for all drugs. (E and F) 10 h treatment with buparlisib or pictilisib induces the accumulation of Dendra2 CMA reporter puncta, but treatment with autophinib does not. Data were pooled from at least three independent experiments. DMSO = 202 cells, buparlisib = 122 cells, pictilisib = 104 cells, and autophinib = 95 cells. (G–I) Effects of buparlisib, pictilisib, and autophinib on macroautophagy, as measured by LC3-II flux, n = 6. For all experiments, cells were maintained in complete growth medium (see Materials and methods). P values written above brackets are derived from unpaired t tests. Two-way ANOVA tables are displayed below graphs where appropriate. Error bars are SEM. Scale bars are 20 µm. ACTB, β-Actin; Aph, autophinib; Bup, buparlisib; Pic, pictilisib.
    Figure Legend Snippet: Effects of PI3K inhibitors on CMA and macroautophagy in AML12 cells. (A–C) Dose curves in AML12 cells for buparlisib, pictilisib, and autophinib, respectively. (D) Western blots demonstrating the effects of buparlisib (5 µM), pictilisib (2 µM), and autophinib (5 µM) on phosphorylation of Akt, MAPKAP1, and GFAP. Blots are representative of six experimental replicates. DMSO is the solvent control for all drugs. (E and F) 10 h treatment with buparlisib or pictilisib induces the accumulation of Dendra2 CMA reporter puncta, but treatment with autophinib does not. Data were pooled from at least three independent experiments. DMSO = 202 cells, buparlisib = 122 cells, pictilisib = 104 cells, and autophinib = 95 cells. (G–I) Effects of buparlisib, pictilisib, and autophinib on macroautophagy, as measured by LC3-II flux, n = 6. For all experiments, cells were maintained in complete growth medium (see Materials and methods). P values written above brackets are derived from unpaired t tests. Two-way ANOVA tables are displayed below graphs where appropriate. Error bars are SEM. Scale bars are 20 µm. ACTB, β-Actin; Aph, autophinib; Bup, buparlisib; Pic, pictilisib.

    Techniques Used: Western Blot, Derivative Assay

    Effects of PI3K inhibitors on CMA and macroautophagy in mIMCD3 cells. (A–C) Dose curves in mIMCD3 cells for buparlisib, pictilisib, and autophinib, respectively. (D) Western blots demonstrating the effects of buparlisib (1 µM), pictilisib (1 µM), and autophinib (5 µM) on phosphorylation of Akt, MAPKAP1, and GFAP. Blots are representative of six experimental replicates. DMSO is the solvent control for all drugs. (E and F) 10 h treatment with buparlisib or pictilisib induces the accumulation of Dendra2 CMA reporter puncta, but treatment with autophinib does not. Data were pooled from at least three independent experiments. DMSO = 373 cells, buparlisib = 85 cells, pictilisib = 112 cells, and autophinib = 204 cells. (G–I) Effects of buparlisib, pictilisib, and autophinib on macroautophagy, as measured by LC3-II flux, n = 6. For all experiments, cells were maintained in complete growth medium (see Materials and methods). P values written above brackets are derived from unpaired t tests. Two-way ANOVA tables are displayed below graphs where appropriate. Error bars are SEM. Scale bars are 20 µm. ACTB, β-Actin; Aph, autophinib; Bup, buparlisib; Pic, pictilisib.
    Figure Legend Snippet: Effects of PI3K inhibitors on CMA and macroautophagy in mIMCD3 cells. (A–C) Dose curves in mIMCD3 cells for buparlisib, pictilisib, and autophinib, respectively. (D) Western blots demonstrating the effects of buparlisib (1 µM), pictilisib (1 µM), and autophinib (5 µM) on phosphorylation of Akt, MAPKAP1, and GFAP. Blots are representative of six experimental replicates. DMSO is the solvent control for all drugs. (E and F) 10 h treatment with buparlisib or pictilisib induces the accumulation of Dendra2 CMA reporter puncta, but treatment with autophinib does not. Data were pooled from at least three independent experiments. DMSO = 373 cells, buparlisib = 85 cells, pictilisib = 112 cells, and autophinib = 204 cells. (G–I) Effects of buparlisib, pictilisib, and autophinib on macroautophagy, as measured by LC3-II flux, n = 6. For all experiments, cells were maintained in complete growth medium (see Materials and methods). P values written above brackets are derived from unpaired t tests. Two-way ANOVA tables are displayed below graphs where appropriate. Error bars are SEM. Scale bars are 20 µm. ACTB, β-Actin; Aph, autophinib; Bup, buparlisib; Pic, pictilisib.

    Techniques Used: Western Blot, Derivative Assay

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars

    • Image Search Results